SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-061278
Filing Date
2023-11-08
Accepted
2023-11-08 17:25:25
Documents
60
Period of Report
2023-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q tpst-20230930.htm   iXBRL 10-Q 2120324
2 EX-10.1 tpst-ex10_1.htm EX-10.1 87191
3 EX-31.1 tpst-ex31_1.htm EX-31.1 20669
4 EX-31.2 tpst-ex31_2.htm EX-31.2 20578
5 EX-32.1 tpst-ex32_1.htm EX-32.1 9721
  Complete submission text file 0000950170-23-061278.txt   6971229

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT tpst-20230930_def.xml EX-101.DEF 164916
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT tpst-20230930_pre.xml EX-101.PRE 277315
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT tpst-20230930.xsd EX-101.SCH 41550
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT tpst-20230930_lab.xml EX-101.LAB 383335
10 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT tpst-20230930_cal.xml EX-101.CAL 37838
54 EXTRACTED XBRL INSTANCE DOCUMENT tpst-20230930_htm.xml XML 1002327
Mailing Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005
Business Address 2000 SIERRA POINT PARKWAY SUITE 400 BRISBANE CA 94005 415-798-8589
Tempest Therapeutics, Inc. (Filer) CIK: 0001544227 (see all company filings)

IRS No.: 451472564 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-35890 | Film No.: 231389340
SIC: 2834 Pharmaceutical Preparations